Archives of Dermatology · 2003 · 121 citations · 14 references
MedicineDermatologyDermatopathologyImmunotherapyPediatric DermatologyInflammatory DermatosesInflammatory Skin DiseasesInflammatory Skin DisordersCorticosteroid-induced Skin AtrophyDermatologic Corticosteroid TherapyTopical Corticosteroid PreparationsTopical Steroid TherapyTreatment Adverse EffectsTreatment With Topical Corticosteroids
Anogenital lichen sclerosus is a chronic inflammatory and fibrosclerotic disease causing significant morbidity, for which topical ultrapotent corticosteroids are the current standard treatment. The study aims to confirm the efficacy of topical tacrolimus for anogenital lichen sclerosus through further clinical trials. The authors treated six patients—three prepubertal girls and three adults—with once‑daily 0.1% tacrolimus ointment. All patients achieved complete resolution with long‑lasting remission up to one year, experienced no major adverse effects, and the treatment was well tolerated, avoiding the skin atrophy seen with corticosteroids.
<h3>Background</h3> Lichen sclerosus of the anogenital area is a chronic inflammatory and fibrosclerotic disease associated with substantial morbidity. Topical ultrapotent corticosteroids are currently the treatment of choice. <h3>Observations</h3> Three prepubertal girls and 3 adults (2 men, 1 woman) were treated with 0.1% tacrolimus ointment once daily. All patients experienced complete resolution with long-lasting remission for up to 1 year. No major adverse effects were observed, and treatment was well tolerated. <h3>Conclusions</h3> Topical tacrolimus is a promising novel agent in the treatment of lichen sclerosus of the anogenital area. A major advantage over topical corticosteroids is the lack of skin atrophy. Further clinical trials are warranted to confirm our findings.
14
A Short-Term Trial of Tacrolimus Ointment for Atopic Dermatitis
Thomas Ruzicka, Thomas Bieber, Erwin Schöpf et al. · New England Journal of Medicine · 1997 · 524 citations · Full text
Medicine, Dermatology, Immunology +16